Calcipotriene Patent Expiration

1. Dovonex patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE39706 LEO PHARMA AS Crystalline form of a vitamin D analogue
Jun, 2015

(9 years ago)

US5763426 LEO PHARMA AS Crystalline form of a vitamin D analogue
Jun, 2015

(9 years ago)




Market Authorisation Date: 22 July, 1996

Treatment: NA

Dosage: CREAM

How can I launch a generic of DOVONEX before it's drug patent expiration?
More Information on Dosage

DOVONEX family patents

Family Patents

2. Dovonex patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5763426 LEO PHARM Crystalline form of a vitamin D analogue
Jun, 2015

(9 years ago)

USRE39706 LEO PHARM Crystalline form of a vitamin D analogue
Jun, 2015

(9 years ago)




Market Authorisation Date: 03 March, 1997

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of DOVONEX before it's drug patent expiration?
More Information on Dosage

DOVONEX family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Sorilux patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8269128 MAYNE PHARMA Vacuum switch tube
May, 2026

(1 year, 10 months from now)

US8629128 MAYNE PHARMA Vitamin formulation
May, 2026

(1 year, 10 months from now)

US8263580 MAYNE PHARMA Vitamin formulation
May, 2028

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Oct 06, 2013
New Indication(I-657) Sep 27, 2015
New Patient Population(NPP) Nov 05, 2022

Market Authorisation Date: 06 October, 2010

Treatment: Use of a calcipotriene containing foam for the treatment of psoriasis; Use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 4 years and older

Dosage: AEROSOL, FOAM

More Information on Dosage

SORILUX family patents

Family Patents